IMMUPHARMA PLC Logo

IMMUPHARMA PLC

IMM | IL

Overview

Corporate Details

ISIN(s):
GB0033711010
LEI:
213800VZKGHXC7VUS895
Country:
United Kingdom
Address:
One, EC1A 7BL London
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

ImmuPharma PLC is a specialty biopharmaceutical company focused on the discovery and development of novel peptide-based therapeutics. The company's core research and development efforts target autoimmune diseases, inflammation, and anti-infectives. Its lead asset, P140 (Lupuzor™), is a peptide therapeutic in late-stage clinical development, including a Phase 3 trial for Systemic Lupus Erythematosus (SLE) and a pivotal Phase 2/3 trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). ImmuPharma utilizes proprietary technology to program the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of its compounds to enhance their therapeutic profiles. The company's business model involves advancing its pipeline and creating value through strategic licensing, partnerships, and collaborations for further development and commercialization.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for IMMUPHARMA PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 14:36
Major Shareholding Notification
Holding(s) in Company
English 52.0 KB
2025-08-06 08:00
Interim Report
Interim Results
English 324.7 KB
2025-06-12 13:51
Post-Annual General Meeting Information
Result of AGM
English 19.8 KB
2025-05-27 16:13
Major Shareholding Notification
Holding(s) in Company
English 52.0 KB
2025-03-14 08:00
Regulatory News Service
IMM attending Bio-Europe Spring 17-19 March,Milan
English 15.9 KB
2025-03-13 08:00
Earnings Release
ImmuPharma proves unique Mechanism of Action-P140
English 18.0 KB
2025-02-21 12:36
Major Shareholding Notification
Holding(s) in Company
English 52.0 KB
2025-02-13 08:00
Share Issue/Capital Change
£2.91m fundraising; related party transactions
English 56.0 KB
2025-01-28 13:57
Regulatory News Service
Response to Share Price Movement
English 13.9 KB
2025-01-09 08:00
Regulatory News Service
Breakthrough Findings into Autoimmune Diseases
English 18.3 KB
2025-01-08 08:00
Regulatory News Service
IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE
English 14.7 KB
2024-12-23 08:00
Audit Report / Information
Change of Auditor
English 11.2 KB
2024-12-10 15:36
Major Shareholding Notification
Holding(s) in Company
English 52.1 KB
2024-12-04 08:00
Board/Management Information
Appointment of Company Secretary
English 14.4 KB
2024-09-09 08:01
Related Party Transaction
Extension of Warrants in Incanthera to 31 Mar 2025
English 20.6 KB

Automate Your Workflow. Get a real-time feed of all IMMUPHARMA PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for IMMUPHARMA PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN